Lipitor, Atorvastatin

Lipitor, Atorvastatin Newswire

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic).

Results 1 - 20 of 562 in Lipitor, Atorvastatin (generic)

  1. Could These Experimental Drugs Eclipse Harvoni's Historic Launch?Read the original story w/Photo

    20 hrs ago | The Motley Fool

    Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark.


  2. Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as ...Read the original story w/Photo

    Friday | PRWeb

    Bernstein Liebhard LLP, which is currently representing clients in the federal Lipitor proceeding, reports that the Court has granted Pfizer's Motion, and has dismissed four individual Lipitor lawsuits without prejudice. It's important to note that this decision impacts only the four individual claims identified by the Court, and will have no effect whatsoever on the thousands of other Lipitor lawsuits currently pending in the District of South Carolina.


  3. The opportunities and challenges of pragmatic point-of-care...Read the original story

    Friday | CiteULike

    The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. Pragmatic trials compare the effects of different decisions in usual clinical practice.


  4. Aridis Pharmaceuticals Appoints Paul-Andre de Lame, M.D., as Chief Medical OfficerRead the original story

    Monday Mar 23 | Freshnews

    Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today the appointment of Paul-Andre de Lame, M.D., as the Company's Chief Medical Officer. Dr. de Lame is an intensive care medical physician with strong experience in cardiovascular medicine and infectious diseases.


  5. Aridis Pharmaceuticals Appoints As Chief Medical OfficerRead the original story

    Sunday Mar 22 | BioSpace

    After several years in clinical practice as anesthesiologist and intensive case specialist, he joined Merck where he was charged with furthering the development of major products, including enalapril and imipenem-cilastatin , then joined , where he was instrumental to the success of atorvastatin . Since, Dr. de Lame founded Anabase International Corp., which provides regulatory and clinical research services, and later, was a co-founder and Chief Medical Officer of Cardiokine Inc. Dr. de Lame was a key contributor to many product development teams involving several vaccines, antibiotics, and antifungals, leading clinical development teams on behalf of companies ranging from start-ups to top ten pharmaceutical manufacturers.


  6. 1 Tiny Biotech's Blockbuster Opportunity in Heart DiseaseRead the original story w/Photo

    Sunday Mar 22 | The Motley Fool

    The U.S. Food and Drug Administration approved the first cholesterol-busting statin drug more than 20 years ago, and statins' proven ability to cut cholesterol levels has turned them into the most widely used drugs in America. However, for millions of people statin therapy alone fails, and that's why Esperion Therapeutics Lipitor every year, heart disease remains the No.


  7. Bernstein Liebhard Lawyers React to Case Documents Released in Federal...Read the original story w/Photo

    Sunday Mar 22 | PRWeb

    Court records updated on March 16, 2015 reflect the filing of nearly 2,100 Lipitor lawsuits in the U.S. District Court, District of South Carolina, where Bernstein Liebhard LLP is representing clients. Given that we are representing clients in the District of South Carolina, we are pleased that the litigation is releasing steady updates pertaining to its progress.


  8. Video: This Rx Combo Might Protect Hearts After MenopauseRead the original story

    Thursday Mar 19 | ClipSyndicate

    Women have a higher risk of heart disease after menopause, but a combination therapy may reduce that risk. I'm Rachelle Grossman with your latest health news.


  9. a Post-Statin World? Tests of Cholesterol Drugs Offer Hope of...Read the original story

    Thursday Mar 19 |

    STATIN WORLD? Tests of Cholesterol Drugs Offer Hope of Reducing Heart Attacks and Strokes. "A new class of experimental cholesterol drugs might sharply reduce the risk of heart attacks and strokes, researchers reported on Sunday, citing what they described as preliminary evidence.


  10. Why Esperion Therapeutics, Inc. is Sky-Rocketing HigherRead the original story

    Thursday Mar 19 | The Motley Fool

    So what : Esperion Therapeutics will bulk up its cash war chest by offering 1.75 million shares of its common stock at a price of $100 per share. The company has also approved an over-allotment program consisting of an additional 262,500 shares.


  11. New cures and treatments could cause pricey headachesRead the original story w/Photo

    Wednesday Mar 18 | Washington Examiner

    Breakthrough drugs for lowering cholesterol and fighting cancer are expected to hit the market over the next few years, saving lives but also leaving the federal government struggling to pay for high-cost drugs without restricting access or resorting to innovation-killing price caps. Drug pricing has received renewed attention lately as public and private health plans struggle to pay for two expensive new hepatitis treatments that carry $1,000-per-pill price tags.


  12. Dr. Roach: The great vitamin debateRead the original story w/Photo

    Wednesday Mar 18 | Lubbock Avalanche-Journal

    Answer : I do not. In my opinion, a healthy diet makes a deficiency of a vitamin or mineral severe enough to weaken the immune system unlikely.


  13. Statin Use in Early Pregnancy Might Be SafeRead the original story

    Tuesday Mar 17 | Journal Watch

    Statin use during the first trimester of pregnancy is not associated with increased risk for congenital malformations, according to an observational study in the BMJ . Statins currently are contraindicated in pregnancy because of concerns about possible teratogenic effects.


  14. Esperion Drug Shows Promise in Cutting Cholesterol LevelsRead the original story

    Tuesday Mar 17 | The Washington Post

    Adding the lowest dose of the drug known as ETC-1002 to treatment with statin drugs like Pfizer Inc.'s Lipitor cut bad LDL cholesterol by 17 percent more than statins alone, the Plymouth, Michigan-based company said in a statement. A higher dose increased the effect, cutting cholesterol by 24 percent.


  15. This New Drug Can Lower Your Cholesterol and Prevent Heart Against DiseasesRead the original story w/Photo

    Tuesday Mar 17 | International Business Times

    A recent study has revealed that adding a new biological drug to the existing class of drugs that helps lower cholesterol level may further improve the results, in addition to lowering the risk of heart diseases, including stroke and attack. According to the research conducted by a group of doctors, the patients who were administered the new class of biological drug were twice less likely to suffer from a cardiac disease as compared to those who were given the conventional treatment, which uses statin drugs such as Lipitor or Zocor.


  16. Now Available: Indoco Remedies Limited (INDOCO) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Tuesday Mar 17 |

    Indoco Remedies Limited is a pharmaceutical company. The company manufactures and markets formulations and active pharmaceutical ingredients.


  17. Esperion Therapeutics Announces Positive Top-Line Phase 2b Results...Read the original story

    Monday Mar 16 | BioSpace

    Esperion Therapeutics Announces Positive Top-Line Phase 2b Results For ETC-1002 Added To Stable Statin Therapy In Patients With Hypercholesterolemia ETC-1002-009 Study Meets Primary Endpoint LDL-Cholesterol Lowering Significantly Greater Than Placebo ETC-1002 Observed to Be Safe and Well-Tolerate Conference Call and Webcast on Tuesday, March 17, 2015 at 8:00 a.m. Eastern Time ANN ARBOR, MI -- -- 03/17/15 -- Esperion Therapeutics, Inc. , an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 compared with placebo in patients with hypercholesterolemia on stable statin therapy.


  18. Some Foods and Supplements Can Interfere with Heart MedicinesRead the original story

    Tuesday Mar 17 | Health News Digest

    Be careful about eating grapefruit if you are one of the many Americans taking a statin drug to lower your cholesterol, nutrition experts at UT Southwestern Medical Center warn. Grapefruit contains chemicals called furanocoumarins that interfere with an enzyme involved in metabolizing many of the statin drugs, including atorvastatin, lovastatin, and simvastatin.


  19. Experimental Drugs Cut Heart RiskRead the original story w/Photo

    Tuesday Mar 17 | The San Diego Union-Tribune

    Drugmakers developing a new generation of cholesterol treatments surged Monday after releasing data that showed the injections cut the rate of major cardiac events and death as they slashed bad cholesterol. Repatha, made by Amgen, and Praluent, under development by Sanofi and Regeneron, both cut LDL, or bad, cholesterol levels by more than 60 percent in studies published Sunday in the New England Journal of Medicine.


  20. Studies Boost Hopes for New Class of Cholesterol MedicinesRead the original story

    Sunday Mar 15 | ABC News

    New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can greatly lower the risk for heart attacks, death and other heart-related problems. The government will decide this summer whether to allow two of these drugs on the market.